

Hajime Uno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7479042/publications.pdf>

Version: 2024-02-01

172
papers

9,497
citations

66250

44
h-index

48101

92
g-index

174
all docs

174
docs citations

174
times ranked

18391
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. <i>Haematologica</i> , 2022, 107, 1172-1180.	1.7	21
2	Geospatial Disparities in the Treatment of Curable Breast Cancer Across the US. <i>JAMA Oncology</i> , 2022, , .	3.4	7
3	Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. <i>Trials</i> , 2022, 23, .	0.7	9
4	Semi-supervised approach to event time annotation using longitudinal electronic health records. <i>Lifetime Data Analysis</i> , 2022, 28, 428-491.	0.4	4
5	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .		10
6	The Effect of Disclosing Life Expectancy Information on Patients' Prognostic Understanding: Secondary Outcomes From a Multicenter Randomized Trial of a Palliative Chemotherapy Educational Intervention. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 1-11.e3.	0.6	13
7	Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals. <i>Familial Cancer</i> , 2021, 20, 111-116.	0.9	5
8	Acrolein and other toxicant exposures in relation to cardiovascular disease among marijuana and tobacco smokers in a longitudinal cohort of HIV-positive and negative adults. <i>EClinicalMedicine</i> , 2021, 31, 100697.	3.2	8
9	Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e236-e247.	1.4	22
10	OptBand: optimization-based confidence bands for functions to characterize time-to-event distributions. <i>Lifetime Data Analysis</i> , 2021, 27, 481-498.	0.4	1
11	Multimorbidity networks associated with frailty among middle-aged and older people with HIV. <i>Aids</i> , 2021, 35, 2451-2461.	1.0	14
12	Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome. <i>Gastroenterology</i> , 2021, 161, 143-150.e4.	0.6	11
13	Predictors of Transition to Frailty in Middle-Aged and Older People With HIV: A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 518-527.	0.9	7
14	Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer. <i>Value in Health</i> , 2021, 25, 69-76.	0.1	2
15	Regarding the Utility of Unstructured Data and Natural Language Processing for Identification of Breast Cancer Recurrence. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1024-1025.	1.0	0
16	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. <i>Cancer Prevention Research</i> , 2021, 14, 1021-1032.	0.7	15
17	Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1829.	3.8	34
18	Parent and Clinician Perspectives on Challenging Parent-Clinician Relationships in Pediatric Oncology. <i>JAMA Network Open</i> , 2021, 4, e2132138.	2.8	5

#	ARTICLE	IF	CITATIONS
19	Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. , 2021, 9, e003323.		0
20	Unrealistic parental expectations for cure in poorâ€prognosis childhood cancer. Cancer, 2020, 126, 416-424.	2.0	34
21	Patientâ€preferred outcomes measurement after postâ€mastectomy radiation therapy and immediate reconstruction. Breast Journal, 2020, 26, 319-321.	0.4	2
22	Goals of care discussions for patients with blood cancers: Association of person, place, and time with endâ€ofâ€life care utilization. Cancer, 2020, 126, 515-522.	2.0	37
23	Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist, 2020, 25, 91-93.	1.9	7
24	Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm₅ Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. Journal of Clinical Oncology, 2020, 38, 4086-4094.	0.8	7
25	Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients With Advanced Cancer. JAMA Oncology, 2020, 6, 1265.	3.4	15
26	ROC curves for clinical prediction models part 1. ROC plots showed no added value above the AUC when evaluating the performance of clinical prediction models. Journal of Clinical Epidemiology, 2020, 126, 207-216.	2.4	51
27	Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology. Clinical Trials, 2020, 17, 597-606.	0.7	2
28	On permutation tests for comparing restricted mean survival time with small sample from randomized trials. Statistics in Medicine, 2020, 39, 2655-2670.	0.8	11
29	Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer. JAMA Network Open, 2020, 3, e206976.	2.8	16
30	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. Journal of Pain and Symptom Management, 2020, 60, 782-789.	0.6	27
31	On the empirical choice of the time window for restricted mean survival time. Biometrics, 2020, 76, 1157-1166.	0.8	53
32	Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials?. Journal of Clinical Oncology, 2020, 38, 2000-2001.	0.8	12
33	Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 193-199.	1.1	11
34	Loss of tetherin antagonism by Nef impairs SIV replication during acute infection of rhesus macaques. PLoS Pathogens, 2020, 16, e1008487.	2.1	8
35	Patterns and predictors of cancerâ€related fatigue in ovarian and endometrial cancers: 1â€year longitudinal study. Cancer, 2020, 126, 3526-3533.	2.0	23
36	How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?. Oncologist, 2019, 24, 867-871.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Effect of Marijuana Smoking on Pulmonary Disease in HIV-Infected and Uninfected Men: A Longitudinal Cohort Study. <i>EClinicalMedicine</i> , 2019, 7, 55-64.	3.2	22
38	Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. <i>Aids</i> , 2019, 33, 145-152.	1.0	13
39	Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. <i>JAMA Surgery</i> , 2019, 154, 466.	2.2	1
40	Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	1.0	11
41	Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. <i>Journal of Oncology Practice</i> , 2019, 15, e616-e627.	2.5	8
42	Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz058.	1.4	4
43	Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-9.	1.0	8
44	Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study. <i>Statistics in Medicine</i> , 2019, 38, 917-932.	0.8	4
45	Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial. <i>Blood</i> , 2019, 134, 67-67.	0.6	5
46	A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials. <i>Statistics in Medicine</i> , 2018, 37, 2307-2320.	0.8	18
47	Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. <i>Clinical Infectious Diseases</i> , 2018, 67, 1182-1190.	2.9	52
48	Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. <i>Annals of Oncology</i> , 2018, 29, 1092-1094.	0.6	14
49	Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors. <i>JAMA Oncology</i> , 2018, 4, 743.	3.4	3
50	Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 306.	3.8	3
51	Interactive or static reports to guide clinical interpretation of cancer genomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 458-464.	2.2	14
52	Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm. <i>Journal of the National Cancer Institute</i> , 2018, 110, 273-281.	3.0	36
53	Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. <i>JAMA Oncology</i> , 2018, 4, 881.	3.4	18
54	Commentary:ÂPREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers. <i>Familial Cancer</i> , 2018, 17, 567-567.	0.9	3

#	ARTICLE	IF	CITATIONS
55	Efficiency of Two Sample Tests via the Restricted Mean Survival Time for Analyzing Event Time Observations. <i>Biometrics</i> , 2018, 74, 694-702.	0.8	58
56	Poor performance of clinical prediction models: the harm of commonly applied methods. <i>Journal of Clinical Epidemiology</i> , 2018, 98, 133-143.	2.4	96
57	Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 585.	3.4	2
58	Determining the Time of Cancer Recurrence Using Claims or Electronic Medical Record Data. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10.	1.0	24
59	Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 825-826.	0.8	5
60	Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 720-721.	0.8	13
61	Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky024.	1.4	21
62	Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-small Cell Lung Cancer. <i>JAMA Network Open</i> , 2018, 1, e183023.	2.8	5
63	Low T-cell subsets prior to development of virus-associated cancer in HIV-seronegative men who have sex with men. <i>Cancer Causes and Control</i> , 2018, 29, 1131-1142.	0.8	7
64	Estrogen-receptor status and risk of contralateral breast cancer following DCIS. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 777-781.	1.1	9
65	Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis. <i>Health Services Research</i> , 2018, 53, 5106-5128.	1.0	13
66	Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. <i>JAMA Oncology</i> , 2018, 4, 1135.	3.4	1
67	Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis. <i>JAMA Oncology</i> , 2018, 4, 1137.	3.4	1
68	Clinical factors associated with urinary tract cancers (UTCs) among Lynch syndrome (LS) patients (Pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1517-1517.	0.8	0
69	Trajectories of medical care cost by service type for recurrent and de novo advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6611-6611.	0.8	0
70	Performance of cancer recurrence algorithms post ICD10 coding scheme switch.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18576-e18576.	0.8	0
71	Hospital variation in outcomes after surgery for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 28-28.	0.8	0
72	Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. <i>Medical Care</i> , 2017, 55, e88-e98.	1.1	52

#	ARTICLE	IF	CITATIONS
73	Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. <i>Science</i> , 2017, 355, .	6.0	988
74	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1086-1095.	0.8	383
75	Long-term nitrite inhalant exposure and cancer risk in MSM. <i>Aids</i> , 2017, 31, 1169-1180.	1.0	12
76	Racial differences in prostate cancer risk in young HIV-positive and HIV-negative men: a prospective cohort study. <i>Cancer Causes and Control</i> , 2017, 28, 767-777.	0.8	7
77	Marijuana Use Impacts Midlife Cardiovascular Events in HIV-Infected Men. <i>Clinical Infectious Diseases</i> , 2017, 65, 626-635.	2.9	23
78	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. <i>JAMA Oncology</i> , 2017, 3, 1692.	3.4	179
79	Decision on performing interim analysis for comparative clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2017, 7, 224-230.	0.5	2
80	Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. <i>JAMA Cardiology</i> , 2017, 2, 1179.	3.0	139
81	Survival after recurrence of stage Iâ€“III breast, colorectal, or lung cancer. <i>Cancer Epidemiology</i> , 2017, 49, 186-194.	0.8	13
82	Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. <i>JAMA Oncology</i> , 2017, 3, 101.	3.4	2
83	Development and Validation of the PREMM₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 2165-2172.	0.8	126
84	Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3373-3373.	0.8	2
85	KIR3DL01 upregulation on gut natural killer cells in response to SIV infection of KIR- and MHC class I-defined rhesus macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006506.	2.1	21
86	Understanding the non-curative potential of palliative chemotherapy: Do patients hear what they want to hear?. <i>Journal of Clinical Oncology</i> , 2017, 35, 6575-6575.	0.8	0
87	Optimizing somatic genomic reporting and physician interpretation with web-based, interactive technologies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1517-1517.	0.8	0
88	Determinants of spending for metastatic breast, lung, and colorectal cancer in SEER-Medicare.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6621-6621.	0.8	0
89	Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. , 2017, , .		0
90	Strmst2 and Strmst2pw: New Commands to Compare Survival Curves Using the Restricted Mean Survival time. <i>The Stata Journal</i> , 2016, 16, 702-716.	0.9	28

#	ARTICLE	IF	CITATIONS
91	Intensity of Medical Interventions between Diagnosis and Death in Patients with Advanced Lung and Colorectal Cancer: A CanCORS Analysis. <i>Journal of Palliative Medicine</i> , 2016, 19, 42-50.	0.6	13
92	Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 173, 713-721.	1.2	7
93	Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. <i>Cancer</i> , 2016, 122, 2091-100.	2.0	57
94	Neratinib after trastuzumab in patients with HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2016, 17, e176.	5.1	3
95	On the Restricted Mean Survival Time Curve in Survival Analysis. <i>Biometrics</i> , 2016, 72, 215-221.	0.8	176
96	How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3818-3818.	0.8	4
97	Safety Study of Salmeterol in Asthma in Adults. <i>New England Journal of Medicine</i> , 2016, 375, 1096-1098.	13.9	3
98	Reply to comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. <i>Cancer</i> , 2016, 122, 3244-3245.	2.0	2
99	Nivolumab in Nonsquamous Non-small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 492-494.	13.9	48
100	Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. <i>European Heart Journal</i> , 2016, 37, 1244-1251.	1.0	206
101	Identification of Lynch syndrome (LS) in patients (pts) without prior LS-associated cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1521-1521.	0.8	0
102	Prevalence of germline cancer susceptibility gene mutations in a consecutive series of 799 colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1501-1501.	0.8	0
103	Survival After Recurrence of Stage III Breast, Colorectal, and Lung Cancer. <i>Journal of Patient-centered Research and Reviews</i> , 2016, 3, 171-172.	0.6	0
104	A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. <i>Statistics in Medicine</i> , 2015, 34, 3680-3695.	0.8	23
105	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. <i>Annals of Internal Medicine</i> , 2015, 163, 127-134.	2.0	162
106	Financial hardship and the intensity of medical care received near death. <i>Psycho-Oncology</i> , 2015, 24, 572-578.	1.0	53
107	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 622-630.	0.4	77
108	Outcomes after palliative re-irradiation of spinal metastases. <i>Journal of Radiation Oncology</i> , 2015, 4, 157-162.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Adverse Outcomes After Palliative Radiation Therapy for Uncomplicated Spine Metastases: Role of Spinal Instability and Single-Fraction Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 373-381.	0.4	58
110	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 2380-2385.	0.8	501
111	Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of Cancer. <i>Annals of Internal Medicine</i> , 2014, 161, 20.	2.0	20
112	Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). <i>Leukemia Research</i> , 2014, 38, 1420-1424.	0.4	9
113	Acute Hospital Care Is The Chief Driver Of Regional Spending Variation In Medicare Patients With Advanced Cancer. <i>Health Affairs</i> , 2014, 33, 1793-1800.	2.5	104
114	Effects of Bracing in Adolescents with Idiopathic Scoliosis. <i>New England Journal of Medicine</i> , 2014, 370, 680-681.	13.9	29
115	Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 496-503.	0.8	121
116	Association Between Breast Cancer Biological Subtype and Risk of Locoregional Recurrence After Mastectomy in Node-Negative Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S244.	0.4	0
117	Adverse Outcomes After Palliative Radiation Therapy for Uncomplicated Spine Metastases: Role of Spinal Instability and Single-Fraction Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S697-S698.	0.4	0
118	A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. <i>Statistics in Medicine</i> , 2013, 32, 2430-2442.	0.8	291
119	Comparative Effectiveness of Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S41.	0.4	0
120	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Tj ETQqO O O rgBT /Overlock 1 Diseases, 2013, 61, 238-246.	2.1	21
121	Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. <i>Clinical Trials</i> , 2012, 9, 570-577.	0.7	68
122	Mortality Rates in Trials of Subjects With Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2012, 1, 8-15.	1.6	71
123	Predicting Binary Outcomes Using Trajectory Classes. <i>Statistics in Biopharmaceutical Research</i> , 2012, 4, 284-292.	0.6	1
124	Monocyte Activation Markers in Cerebrospinal Fluid Associated With Impaired Neurocognitive Testing in Advanced HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 234-243.	0.9	158
125	Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: Effect of specimen source (bone marrow or peripheral blood) on assay readouts. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 158-172.	0.7	27
126	Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbeopetin Alfa. <i>Circulation</i> , 2011, 124, 2903-2908.	1.6	89

#	ARTICLE	IF	CITATIONS
127	Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. <i>American Heart Journal</i> , 2011, 162, 548-554.	1.2	150
128	Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). <i>American Heart Journal</i> , 2011, 162, 748-755.e3.	1.2	72
129	Outcome prediction in sepsis combined use of genetic polymorphisms " A study in Japanese population. <i>Cytokine</i> , 2011, 54, 79-84.	1.4	32
130	Plasma sCD14 Is a Biomarker Associated With Impaired Neurocognitive Test Performance in Attention and Learning Domains in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 371-379.	0.9	174
131	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2011, 118, 4359-4362.	0.6	39
132	Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. <i>British Journal of Haematology</i> , 2011, 155, 340-348.	1.2	29
133	Graphical Procedures for Evaluating Overall and Subject-Specific Incremental Values from New Predictors with Censored Event Time Data. <i>Biometrics</i> , 2011, 67, 1389-1396.	0.8	10
134	Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 717-728.	2.1	123
135	Opposing Effects of β Blockers and Angiotensin-Converting Enzyme Inhibitors on Development of New-Onset Diabetes Mellitus in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2011, 107, 1705-1709.	0.7	15
136	On the C \hat{c} statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. <i>Statistics in Medicine</i> , 2011, 30, 1105-1117.	0.8	972
137	Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. <i>European Heart Journal</i> , 2011, 32, 1720-1729.	1.0	107
138	Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 845-855.	2.2	53
139	Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction. <i>Circulation</i> , 2011, 123, 2674-2680.	1.6	18
140	Dyssynchrony, Contractile Function, and Response to Cardiac Resynchronization Therapy. <i>Circulation: Heart Failure</i> , 2011, 4, 433-440.	1.6	71
141	Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 483-490.	1.0	18
142	Response to Letter Regarding Article, "Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both". <i>Circulation</i> , 2011, 123, .	1.6	0
143	Clinical consequences of road traffic injuries among the elderly in Japan. <i>BMC Public Health</i> , 2010, 10, 375.	1.2	10
144	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195

#	ARTICLE	IF	CITATIONS
145	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 1146-1155.	13.9	433
146	The interrelationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010, 12, 1229-1237.	2.9	45
147	Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 121, 1096-1103.	1.6	96
148	Calibrating parametric subject-specific risk estimation. <i>Biometrika</i> , 2010, 97, 389-404.	1.3	35
149	Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1812-1822.	1.2	263
150	Defibrotide for the Treatment of Severe Hepatic Venoo-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1005-1017.	2.0	227
151	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. <i>Blood</i> , 2010, 116, 4077-4085.	0.6	188
152	Single-Cell Network Profiling (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010, 116, 2695-2695.	0.6	1
153	Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7. <i>Blood</i> , 2010, 116, 579-579.	0.6	0
154	Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling. <i>Blood</i> , 2010, 116, 2739-2739.	0.6	0
155	Specimen Source (BM or PB) Does Not Affect Proteomic Signaling In Patients with AML and Circulating Blasts. <i>Blood</i> , 2010, 116, 2693-2693.	0.6	0
156	Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2009, 1, 348-355.	0.6	17
157	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009, 54, 59-69.	2.1	60
158	Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. <i>British Journal of Haematology</i> , 2009, 147, 677-680.	1.2	50
159	Diagnostic performance of PET/CT in differentiation of malignant and benign non-solid solitary pulmonary nodules. <i>Annals of Nuclear Medicine</i> , 2008, 22, 571-577.	1.2	32
160	Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 389-395.	1.2	5
161	Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1199-1206.	1.2	12
162	Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. <i>European Heart Journal</i> , 2008, 30, 56-65.	1.0	117

#	ARTICLE	IF	CITATIONS
163	The Short Treatment with the Angiotensin Receptor Blocker Candesartan Surveyed by Telemedicine (STAR CAST) Study: Rationale and Study Design. <i>Hypertension Research</i> , 2008, 31, 1843-1849.	1.5	10
164	Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models. <i>Bioinformatics</i> , 2007, 23, 732-738.	1.8	7
165	Evaluating Prediction Rules for Year Survivors With Censored Regression Models. <i>Journal of the American Statistical Association</i> , 2007, 102, 527-537.	1.8	281
166	Development and validation of diagnostic prediction model for solitary pulmonary nodules. <i>Respirology</i> , 2007, 12, 856-862.	1.3	49
167	Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 313-318.	1.1	4
168	Solitary pulmonary granuloma caused by <i>Mycobacterium avium-intracellulare</i> complex. <i>International Journal of Tuberculosis and Lung Disease</i> , 2007, 11, 215-21.	0.6	10
169	Diagnostic accuracy of CT-guided percutaneous cutting needle biopsy for thymic tumours. <i>Clinical Radiology</i> , 2006, 61, 771-775.	0.5	24
170	Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 237-241.	1.1	30
171	The optimal confidence region for a random parameter. <i>Biometrika</i> , 2005, 92, 957-964.	1.3	6
172	Prediction of Lung Adenocarcinoma Without Vessel Invasion. <i>Chest</i> , 2005, 128, 3276-3283.	0.4	15